AMENDMENTS TO THE CLAIMS:

Please amend the claims as follows:

1. (Currenlty amended) A compound of Formula (I) or a salt, or solvate, ~~or physiologically functional derivative~~ thereof:



(I)

wherein:

- R1 is hydrogen or C_{1-6}alkyl or as indicated by the dotted line is fused to the phenyl forming a 5 or 6 membered ring, optionally containing a double bond;
- n is 0, 1, 2, 3 or 4;
- R2 is aryl, optionally substituted by one or two groups selected from the group consisting of halogen, NH_2, hydroxy, cyano, C_{1-4}alkyl, C_{1-4}alkoxy, C_{1-4}alkanoyl, haloC_{1-4}alkyl, haloC_{1-4}alkoxy, aryl, aryloxy, C_{1-4}alkoxycarbonyl, C_{1-4}alkylsulfonyl and a group $R_3R_4NSO_2$ (wherein R_3 and R_4 are independently hydrogen or C_{1-4}alkyl), $(CH_2)_{0-3}NHCOOC_{1-4}$alkyl, and a 5- or 6-membered heteroaryl group;
- or n is 0 and R1 and R2, together with the nitrogen atom to which they are joined, form a 5- or 6-membered monocyclic heterocyclic ring or a 9- or 10-membered bicyclic heterocyclic ring wherein at least the ring which contains the nitrogen atom to which R1 and R2 are joined is non-aromatic, and wherein the 5- or 6-membered monocyclic heterocyclic ring or the 9- or 10-membered bicyclic heterocyclic ring is optionally substituted by one or two groups selected from the group consisting of halogen, hydroxy, cyano, oxo, C_{1-4}alkyl, C_{1-4}alkanoyl, C_{1-4}alkoxy, haloC_{1-4}alkyl, haloC_{1-4}alkoxy, aryl, aryloxy and C_{1-4}alkoxycarbonyl; and
- X is indazolyl, pyrazolyl or a group



wherein

G is CH or N; and

Y_1 and Y_2 are independently hydrogen, halogen and a group NR5R6 (wherein R5 and R6 are independently hydrogen, C_{1-6}alkyl, C_{2-6}alkenyl, or



).

2. (Original) A compound as claimed in claim 1, wherein R1 is hydrogen.

3. (Currently amended) A compound as claimed in claim 1~~ or claim 2~~, wherein n is 1 or 2.

4. (Currently amended) A compound as claimed in claim 1~~any of claims 1-3~~, wherein R2 is aryl, optionally substituted by one or two groups selected from the group consisting of halogen and C_{1-4}alkoxy.

5. (Currently amended) A compound as claimed in claim 1~~ or claim 2~~, wherein n is 0 and R1 and R2, together with the nitrogen atom to which they are joined, form a 6-membered monocyclic heterocyclic ring or a 10-membered bicyclic heterocyclic ring wherein at least the ring which each contains the nitrogen atom to which R1 and R2 are joined is non-aromatic, wherein the 6-membered monocyclic heterocyclic ring or 10-membered bicyclic heterocyclic ring are both optionally substituted by one or two groups selected from oxo, C_{1-4}alkyl, phenyl and C_{1-4}alkoxycarbonyl.

6. (Currently amended) A compound as claimed in claim 1~~any of claims 1–5~~, wherein X is indazolyl or pyrazolyl.

7. (Currently amended) A compound as claimed in claim 1~~any of claims~~



~~1-5~~, wherein X is a group:

wherein Y_1 is hydrogen or halogen.

8. (Currently amended) A compound as claimed in claim 1 ~~any of claims 1-5~~, wherein X is a group:



wherein one of Y_1 and Y_2 is hydrogen, and the other is hydrogen, halogen or a group NR5R6 whrein R5 and R6 are independently hydrogen, C_{1-6}alkyl or C_{2-6}alkenyl.

9. (Currently amended) A compound as claimed in claim 1, wherein said compound is selected from the group consisting of~~which is~~:

N-benzyl-4-(4-pyridinyl)benzamide;
N-(2-phenylethyl)-4-(4-pyridinyl)benzamide;
N-(3-methoxybenzyl)-4-(4-pyridinyl)benzamide;
N-(3-methoxybenzyl)-4-(1H-pyrazol-4-yl)benzamide;
4-(2-chloro-4-pyridinyl)-N-(3-methoxybenzyl)benzamide;
4-(2-amino-4-pyrimidinyl)-N-(3-methoxybenzyl)benzamide;
N-(3-methoxybenzyl)-4-(4-pyrimidinyl)benzamide;
4-[6-(allylamino)-4-pyrimidinyl]-N-(3-methoxybenzyl)benzamide;
4-[6-amino-4-pyrimidinyl]-N-(3-methoxybenzyl)benzamide;
4-(1H-indazol-5-yl)-N-(3-methoxybenzyl)benzamide;
4-(2-amino-4-pyrimidinyl)-N-{[3-(methyloxy)phenyl]methyl}benzamide;
4-(2-{[4-(methyloxy)phenyl]amino}-4-pyrimidinyl)-N-{[3-(methyloxy)phenyl]methyl}benzamide;

4-(2-amino-4-pyrimidinyl)-N-[(2-chlorophenyl)methyl]benzamide;
4-(2-amino-4-pyrimidinyl)-N-[(4-fluorophenyl)methyl]benzamide;
4-(2-amino-4-pyrimidinyl)-N-[(4-chlorophenyl)methyl]benzamide;
4-(2-amino-4-pyrimidinyl)-N-[(2-fluorophenyl)methyl]benzamide;
4-(2-amino-4-pyrimidinyl)-N-{[2-(methyloxy)phenyl]methyl}benzamide;
4-(2-amino-4-pyrimidinyl)-N-[(2-methylphenyl)methyl]benzamide;
4-(2-amino-4-pyrimidinyl)-N-{[4-(methyloxy)phenyl]methyl}benzamide;
4-(2-amino-4-pyrimidinyl)-N-(2,3-dihydro-1H-inden-1-yl)benzamide;
4-(2-amino-4-pyrimidinyl)-N-[(1R)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide;
4-(2-amino-4-pyrimidinyl)-N-{[3-(trifluoromethyl)phenyl]methyl}benzamide;
1,1-dimethylethyl({3-[({[4-(2-amino-4-
pyrimidinyl)phenyl]carbonyl}amino)methyl]phenyl}methyl)carbamate;
4-(2-amino-4-pyrimidinyl)-N-[(3-bromophenyl)methyl]benzamide;
4-(2-amino-4-pyrimidinyl)-N-[(3-chlorophenyl)methyl]benzamide;
4-(2-amino-4-pyrimidinyl)-N-[(3-fluorophenyl)methyl]benzamide;
4-(2-amino-4-pyrimidinyl)-N-(phenylmethyl)benzamide;
4-(2-amino-4-pyrimidinyl)-N-{(1S)-1-[4-(methyloxy)phenyl]ethyl}benzamide;
4-(2-amino-4-pyrimidinyl)-N-[(1S)-1-phenylpropyl]benzamide;
6-(2-amino-4-pyrimidinyl)-2-(phenylmethyl)-1(2H)-isoquinolinone;
4-(2-amino-4-pyrimidinyl)-N-[(3-hydroxyphenyl)methyl]benzamide;
4-(2-amino-4-pyrimidinyl)-N-({3-[(difluoromethyl)oxy]phenyl}methyl)benzamide;
4-(2-amino-4-pyrimidinyl)-N-(1-methyl-1-phenylethyl)benzamide;
4-(2-amino-4-pyrimidinyl)-N-[(3,5-dichlorophenyl)methyl]benzamide;
4-(2-amino-4-pyrimidinyl)-N-(4-biphenylylmethyl)benzamide;
4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylethyl]benzamide;
1,1-dimethylethyl{3-[1-({[4-(2-amino-4-
pyrimidinyl)phenyl]carbonyl}amino)ethyl]phenyl}carbamate;
N-[(2-aminophenyl)methyl]-4-(2-amino-4-pyrimidinyl)benzamide;
4-(2-amino-4-pyrimidinyl)-N-[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]benzamide;
5-(2-amino-4-pyrimidinyl)-2-(phenylmethyl)-2,3-dihydro-1H-isoindol-1-one;
4-(2-amino-4-pyrimidinyl)-N-{(1R)-1-[3-(methyloxy)phenyl]ethyl}benzamide; and
4-(2-amino-4-pyrimidinyl)-N-[(1R)-1-phenylpropyl]benzamide;

or a salt, or solvate ~~or physiologically functional derivative~~ thereof.

10-11. (Cancelled).

12. (Currently amended) A method of treating a disorder in a mammal, said disorder being mediated by inappropriate ROCK-1 activity, comprising: administering to said mammal a therapeutically effective amount of a compound as defined in claim 1~~any of claims 1-9~~.

13. (Cancelled).

14. (Currently amended) A pharmaceutical composition comprising a therapeutically effective amount of a compound as defined in claim 1~~any of claims 1-9~~ and one or more of pharmaceutically acceptable carriers, diluents and excipients.